Examining the Utility of a Novel Neurologic Test in Patients With Obstructive Sleep Apnea: A Pilot Study

Michael L. Grover, Lori Latowski Grover, Martina Mookadam, Lanyu Mi, Yu-Hui Chang, and James Parish

Abstract

Purpose: To test the association between participant King-Devick Test (KDT) times and obstructive sleep apnea (OSA) severity and evaluate for improvement after continuous positive airway pressure (CPAP) treatment. Methods: Study dates January 30 to July 31, 2018. Patients were referred for initial evaluation of sleep disordered breathing concerns. OSA severities were defined by Apnea Hypopnea Index (AHI) results, with ≥15 considered at least moderate OSA. The KDT is an objective physical measure of brain function. We estimated correlation between KDT time and AHI and compared mean KDT time between patients with and without moderate OSA. For the OSA subgroup, we evaluated for potential improvement in KDT after CPAP. Results: We enrolled 60 participants, of whom 35 (58.3%) had OSA with an AHI ≥15. Initial analyses noted no significant KDT time differences between patients based on OSA severity. However, after excluding 3 participants who had baseline neurologic illness, adjusted analyses demonstrated that mean KDT time was significantly prolonged for patients with moderate or greater OSA (AHI ≥15) as compared to those with mild or no sleep apnea (AHI <15): 63.4 seconds (95% CI 58.9-67.8) versus 55.7 seconds (95% CI 50.2-61.1), P = .03. CPAP-treated subjects demonstrated significantly improved KDT test times: 63.5 seconds mean pretreatment versus 55.6 posttreatment; −6.6 seconds mean difference, 95%CI (−12.0, −1.13), P = .02. Conclusion: Neurologic abnormalities in patients with OSA are potentially demonstrable utilizing this objective physical measure. Significant improvement is achieved in patients after CPAP treatment.

Keywords
treatment, risk assessment, apnea, sleep, dysfunction, neurologic, medical device

Introduction

Clinical evaluation of suspected obstructive sleep apnea (OSA) is reliant on subjective reports of excessive daytime sleepiness, snoring, or witnessed apnea. These require patient recognition or bed partner recall, either of which may be inaccurate or unavailable. Although clinical guidelines suggest utilizing reports of excessive sleepiness as the preferred method to target OSA suspects for evaluation, this does not always reliably differentiate those patients with or without OSA. Direct measurement of the impaired brain function caused by sleep deprivation and hypoxia has the potential to augment clinicians’ suspicion of disease and objectively assist in patient risk stratification.

The King-Devick Test (KDT) in association with Mayo Clinic is a rapid number naming test used in baseline assessments and remove from play decisions for concussion. The KDT is an objective physical measure of neurologic function, allowing assessment in a quick, easily administered manner. Rapid number naming requires saccades, attention, and language, as well as other areas involved in reading. It evaluates function of the brainstem, cerebellum, and cerebral cortex. Abnormalities in saccadic eye movements have been shown to be associated with sleep deprivation, hypoxia, and cognitive impairment—issues frequently found in patients with OSA. Prior work has demonstrated significant KDT time differences related to neurologic conditions such as dementia and Parkinson’s disease. The test is effective at detecting acute

1 Mayo Clinic, Scottsdale, AZ, USA
2 Southern College of Optometry, Memphis, TN, USA

Corresponding Author:
Michael L. Grover, Mayo Clinic Thunderbird Primary Care Center–Family Medicine, 13737 North 92nd Street, Scottsdale, AZ 85260, USA.
Email: grover.michael@mayo.edu

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
hypoxic impairment, even at early presymptomatic stages, so
has promise in OSA where patients may experience repeated
hypoxic events.7,11 The KDT has been utilized in a few small
studies of sleep restricted or deprived subjects, but had not
been employed previously in a study of OSA suspect patients.7,8

Our objective was to obtain baseline KDT times for
patients suspected of OSA presenting to the Mayo Clinic
Arizona Sleep Center. We hypothesized correlation between
slower KDT times (ie, worse function) and greater severity of
OSA. We also hypothesized that patients with OSA who
adhered to continuous positive airway pressure (CPAP)
treatment would demonstrate improvement in brain func-
tion as measured by decreased KDT times compared with
baseline.

Methods

The Mayo Clinic Foundation Institutional Review Board
approved this pilot cohort study for human subject research.
We enrolled patients from January 20, 2018 to March 27,
2018 and then completed follow-up assessments until July
31, 2018. Our subjects of interest for inclusion were patients
referred to the Mayo Clinic Arizona Hospital Sleep Center
by Sleep Medicine Division providers for initial evaluation
of sleep disordered breathing concerns. These patients
received initial information about the study purposes during
their consultation with providers. Written informed consent
was obtained by a research coordinator in the Sleep Center
on the night of their scheduled polysomnography. Patients
were screened for exclusion criteria (eg, visual impairment
which precluded testing, previous OSA diagnosis and treat-
ment) As this was a small pilot study intended to provide
proof of concept and explore feasibility, we made a decision
to include patients with neurologic illnesses in our cohort.

We recruited subjects until we accrued 60 participants.
Our sample size of 60 patients was determined based on the
following power analysis. Assuming type I error 0.05 and
the correlation coefficient 0.36 (weak correlation between
Apnea Hypopnea Index [AHI] and KDT), we had 80%
power to detect that this correlation was significant. We pre-
sumed that half of patients would have moderate to severe
sleep apnea (as defined by an AHI ≥15; 30 patients) and
would be candidates for CPAP. Subjects who had less severe
OSA, but who were offered CPAP by their sleep medicine
provider, would also be included in the OSA treatment sub-
group. This size treatment cohort would produce at least
80% power to detect a 0.55 standard deviation difference in
the pre- and posttreatment KDT.

Data Collection

The KDT was administered by research coordinators. These
individuals were trained on its use and demonstrated profi-
ciency. Data were collected in a standardized fashion. We
measured KDT times (in seconds) for the 60 accrued sub-
jects in the evening of their scheduled polysomnography.
Following testing, those who were diagnosed with OSA and
treated with CPAP had a follow-up, posttreatment KDT
administered by the coordinator at their compliance visit
during clinic hours. This visit was accomplished between
60 and 90 days from the initiation of treatment.

While subjects were in the Sleep Center and after obtain-
ing consent, the coordinator collected demographic informa-
tion (eg, age, gender, weight, body mass index) as well as data
necessary for calculation of a Sleep Apnea Clinical Score
(SACS).12 These include presence or absence of hypertension,
a measured neck circumference, and reported frequency of
snoring and witnessed apnea. Our research group has recently
published a study providing external validation of the SACS
and has proposed a care process model utilizing it for risk
stratification along with selective use of oximetry.13,14 The
SACS has been a commonly used clinical prediction tool at
Mayo Clinic, especially in preoperative evaluations.15

Data Handling

Polysomnography outcomes and other clinical data were
transferred from the sleep lab database. This information as
well as demographic data and the SACS were entered to a
REDCap database. All study data were stored in a pass-
word-protected electronic database and were handled
according to HIPPA regulations. A study number was
assigned to each patient and all identifying information was
removed. Demographic and clinical data were entered in
REDCap by the study coordinators. The study statistician
transferred the data to SAS format for statistical analysis.
The database has been archived after study completion.

Data Analysis

Descriptive statistics summarized demographic and clinical
characteristics of the cohort. We estimated the correlation
between KDT and AHI and compared the mean KDT
between patients with and without OSA by the 2-sample
t test. For the OSA treatment subgroup, we measured the
improvement in KDT before and after the use of CPAP by the
paired t test. The utilization of CPAP was quantified by the
number of nights used and the hours of use per night. We also
examined the reduction of AHI achieved by CPAP treatment.
The results were reported as point estimates and 95% confi-
dence intervals (CIs). The analysis was conducted by SAS
9.4 (SAS Institute) and R 3.4.4 (R Core Team). All tests were
2-sided and P < .05 was considered statistically significant.

Results

The study flow diagram can be seen in Figure 1. We
approached 126 patients having polysomnography in the
Mayo Clinic Hospital Sleep Center and 60 subjects were accrued. Most screening failures (48/56; 86%) were due to patients having a previously established OSA diagnosis. Only 10/126 approached patients (8%) actually declined participation. Demographic and clinical characteristics as stratified by OSA severity are seen in Table 1. Patients who had moderate or greater OSA were more likely to be obese, have diabetes and have a higher SACS.

**Baseline Cohort Analyses**

KDT time duration was correlated to AHI result on polysomnography neither as a continuous variable (Figure 2) nor as a categorical variable (Table 2) with our initial analyses of all 60 subjects. However, we noted that patients who had underlying neurologic illnesses (i.e., mild cognitive impairment, dementia, and Parkinson’s disease) had prolonged baseline KDT times (as noted in Figure 3 and highlighted in red). We elected to remove these 3 participants from an adjusted analysis cohort. This updated analysis demonstrated that there was still not a significant association between KDT time and AHI as a continuous variable; Pearson correlation coefficient 0.10, 95%CI (−0.16, 0.35). There was now noted, however, a significant association in the adjusted analysis by examining AHI as a categorical variable (Table 3). KDT time was significantly prolonged for those patients with moderate or greater OSA (AHI ≥ 15) compared to those with no OSA or mild OSA (AHI < 15); 63.4 mean time in seconds versus 55.7 seconds; 95%CI (58.9–67.8), P = .03.

**OSA Treatment Subgroup**

Thirty-seven participants were offered CPAP, 35 with AHI ≥ 15 and 2 with lower AHI (see Figure 1). We elected to exclude the one patient with a diagnosis of dementia, who was on CPAP, from the treatment subgroup in order to be consistent between the pre- and posttreatment cohorts. Twenty-two of these 36 total patients initiated CPAP treatment and followed up for a CPAP compliance visit (61%).

![Figure 1. Study flow diagram.](#)

CPAP, continuous positive airway pressure; AHI, Apnea Hypopnea Index; KDT, King-Devick Test.
.visitors" to Arizona and were away during the follow-up period, and 1 returned for a CPAP compliance visit but was missed and did not complete the repeat KDT. No significant differences were noted in demographic or clinical characteristics between those who adhered to both treatment and follow-up plans and those participants who did not. Patients treated with CPAP were highly compliant, with a mean use of CPAP for 28.3 days out of the past 30 and a mean of 6.4 hours of use per night. Mean AHI pretreatment was 29.8 and mean AHI posttreatment with CPAP was 3.6; \( P < .001 \), mean difference −27, 95% CI (−35.1, −18.2).

CPAP treatment was associated with a significantly improved KDT time, reflecting improvement in neurologic function. KDT time was noted to be 63.5 seconds mean pretreatment versus 55.6 mean seconds posttreatment, creating a −6.6 seconds mean difference, \( P = .02 \), 95% CI (−12.0, −1.13) (Table 4).

### Discussion

Patients with sleep disordered breathing who have moderate or greater OSA on polysomnography may be more likely to have neurologic dysfunction as demonstrable by slower times on the KDT. This testing difference might not be perceptible, however, if patients have concomitant underlying nervous system illness at baseline, such as Parkinson’s disease or dementia. The treatment effect of CPAP on the associated neurologic dysfunction found in patients with OSA was demonstrated by significant time improvements on the

### Table 1. Demographic and Clinical Characteristics of All Subjects by OSA Severity.

|                         | Mild/No OSA (\( AHI \leq 15, AHI < 5 \)) (\( N = 25, \text{Mean} = 6.4 \)) | Moderate OSA (\( AHI \geq 15, AHI \leq 30 \)) (\( N = 25, \text{Mean} = 20.9 \)) | Severe OSA (\( AHI > 30 \)) (\( N = 10, \text{Mean} = 61.8 \)) | Total (\( N = 60 \)) | \( P \) |
|-------------------------|---------------------------------------------------------------------------------|---------------------------------------------------------------------------------|-----------------------------------------------------------------|----------------------|-------|
| Age at enrollment, years |                                                                                 |                                                                                |                                                                 |                      |       |
| Mean (SD)               | 60.5 (16.65)                                                                     | 64.4 (10.87)                                                                    | 66.5 (15.41)                                                     | 63.1 (14.24)         |       |
| Median                  | 65.9                                                                            | 67.6                                                                            | 69                                                              | 67.4                 |       |
| Range                   | (19.4-80.7)                                                                     | (39.5-79.5)                                                                     | (35.3-85.2)                                                     | (19.4-85.2)          |       |
| Gender                  |                                                                                  |                                                                                 |                                                                |                      |       |
| Female                  | 9 (36.0%)                                                                       | 9 (36.0%)                                                                       | 2 (20.0%)                                                       | 20 (33.3%)           | .63   |
| Male                    | 16 (64.0%)                                                                      | 16 (64.0%)                                                                      | 8 (80.0%)                                                       | 40 (66.7%)           |       |
| BMI                      |                                                                                   |                                                                                 |                                                                |                      | .02   |
| Mean (SD)               | 28.5 (5.76)                                                                     | 31.2 (5.12)                                                                     | 35.3 (9.19)                                                     | 30.8 (6.53)          |       |
| Median                  | 26.8                                                                            | 30.7                                                                            | 33.7                                                            | 29.8                 |       |
| Range                   | (21.5-42.3)                                                                     | (24.6-45.0)                                                                     | (22.2-55.7)                                                     | (21.5-55.7)          |       |
| Diabetes                |                                                                                  |                                                                                 |                                                                |                      | .04   |
| No                      | 24 (96.0%)                                                                      | 18 (72.0%)                                                                      | 7 (70.0%)                                                       | 49 (81.7%)           |       |
| Yes                     | 1 (4.0%)                                                                        | 7 (28.0%)                                                                       | 3 (30.0%)                                                       | 11 (18.3%)           |       |
| Total Sleep Apnea Clinical Score |                                                                                   |                                                                                 |                                                                |                      | .01   |
| Mean (SD)               | 6.8 (5.93)                                                                       | 13.6 (10.77)                                                                     | 16.6 (14.55)                                                    | 11.3 (10.46)         |       |
| Median                  | 5                                                                                | 11                                                                              | 11                                                              | 8                    |       |
| Range                   | (0.0-18.0)                                                                      | (1.0-40.0)                                                                      | (2.0-48.0)                                                      | (0.0-48.0)           |       |

Abbreviations: OSA, obstructive sleep apnea; AHI, apnea hypopnea index; SD, standard deviation; ANOVA, analysis of variance.

\(^a\)ANOVA F test.

\(^b\)Fisher’s exact test.

**Figure 2.** Correlation of King-Devick Test (KDT) time duration in seconds versus Apnea Hypopnea Index (AHI) from patient polysomnography.
The ability to describe a “normal” KDT is limited. No conclusive normative data yet exist across large populations based on a patient’s age, gender, other demographic factors, or medical characteristics. Comparison of the current patient performance on KDT against their personal baseline is the optimal way to utilize these data.

The KDT is most often used in baseline assessment of neurologic function in athletes at risk for concussion. In this scenario, the baseline assessment allows for comparison with KDT time after a head injury event, when it may demonstrate a slower time. This provides objective evidence of neurologic performance impact. Return-to-play decisions can be made based on noted improvement over time back to baseline.

While the obstruction noted in OSA is rightly conceptualized as being a result of a pulmonary airflow abnormality, the physiologic effects are demonstrated in multiple organ systems, including the neurologic system. Demonstration of the treatment efficacy of CPAP has traditionally been confirmed by resolution of that obstruction via recordings of decreased AHI to normal (ie, <5). While the American College of Physicians’ Guidelines on Management of OSA in Adults noted moderate quality evidence that “CPAP improves sleep measures compared with control or sham devices in patients with at least moderate OSA (AHI score ≥ 15 events/h), there was little or no evidence on CPAP on other important clinical outcomes.” There are now some initial compelling data that saccadic eye movement testing, such as with the KDT, might provide opportunity for an objective pre- and post-CPAP comparator tool to confirm improvement in neurologic function. Objective physical measurement of neurologic improvement has potential to augment standard OSA management.

Unfortunately, in this small pilot study designed to test feasibility and demonstrate proof of concept, the confidence intervals in KDT time ranges noted between “normal” and “abnormal” subjects overlap, making their clinical significance unclear. However, a larger, multicenter study enrolling more subjects, perhaps with age and gender matched asymptomatic controls, might provide an opportunity to develop needed normative data or, at a minimum, generate risk stratification thresholds to aid clinicians caught in diagnostic dilemmas about how best to proceed in the work up of OSA suspect patients. Use of the KDT, perhaps in combination with clinical prediction rules like SACS, has potential to optimize risk stratification by proving more objective, easily obtainable clinical information which could then allow prioritization of testing for those with demonstrated neurologic dysfunction from their sleep-related breathing issues.

For patients who are found to have no OSA or mild disease and, therefore, are not candidates for CPAP, use of the KDT to monitor patients over time also conceptually holds promise. Conceivably, patients could check their KDT time at home on a regular basis and return for clinical reassessment with their providers if their objectively measured brain function was to worsen.

Assessment of CPAP treatment effect by KDT has potential to augment OSA patient management. While resolution

### Table 2. King-Devick Test (KDT) Time Association With Obstructive Sleep Apnea (OSA) Outcome by Apnea Hypopnea Index (AHI) Categories.

| Groups          | Frequency (Percentage) | Group Mean of KDT (SE) | 95% CI for Group Mean of KDT | P    |
|-----------------|------------------------|------------------------|-----------------------------|------|
| OSA (AHI ≥ 15)  | Yes                    | 35 (58.3)              | 64.9 (3.16)                 | (58.6, 71.2) | .43 |
|                 | No                     | 25 (41.7)              | 61.0 (3.74)                 | (53.5, 68.5) |    |
| OSA (AHI ≥ 5)   | Normal                 | 9 (15.0)               | 59.6 (6.24)                 | (47.2, 72.1) | .53 |
|                 | Abnormal               | 51 (85.0)              | 63.9 (2.62)                 | (58.7, 69.1) |    |

Figure 3. Adjusted analysis of King-Devick Test time versus Apnea Hypopnea Index as a continuous variable after eliminating 3 subjects with underlying neurologic illness (highlighted in red). Pearson correlation coefficient (95% CI): 0.10 (−0.16, 0.35).
of obstruction is noted at CPAP compliance visits via the AHI returning to normal, there may be equal import in demonstrating the improved brain function for an individual patient. It is possible that this knowledge could be a powerful motivator for behavioral changes for patients and create increased incentives for continued adherence to treatment. This hypothesis could be evaluated in future patient-oriented outcome studies. The KDT time could be used as an objective measure quantifying a patient’s subjective sense of improved wellbeing after treatment.

Conceivably, monitoring of KDT time may have utility for individual patients with milder disease or for those receiving non-CPAP treatments, such as mandibular advancement devices, positional therapy, and surgical interventions. Worsening times on the KDT could alert patients that there is a need for clinical reevaluation with their physicians.

**Strengths and Limitations**

These data are generated in a small number of subjects at a single institution, which potentially limit their generalizability to other settings. Our sample size calculations were set based on the smallest necessary enrollment cohort needed to find differences in KDT between those with and without disease. For convenience in this pilot study, we only included those being tested in a sleep lab with polysomnography and did not seek to include those who had home based testing. We recognize the need in future studies to control for confounding factors for neurologic performance on this function test, such as age and medical condition, especially dementia, Parkinsonism, and other issues. We would contemplate retesting all subjects to examine more fully if there might be improvements in testing based on learning and repetition. Preforming the KDT on age and gender matched controls that were not suspected of OSA might help generate needed normative data.

This pilot study offered no patient reward or inducement for participation. We relied on the typical clinical processes of appointment scheduling and reminders for follow up to occur in the CPAP treatment group. This is when we documented compliance and obtained the follow-up KDT. The rates of adherence, while admittedly not ideal, reflect the imperfection of routine clinical practice. Despite lower than expected numbers of CPAP treatment patients completing all study follow-up procedures, significant improvements in KDT times from baseline were still noted.

Completing implementation and dissemination studies in both sleep medicine specialty practices and, as importantly, in the primary care setting, would discover if both clinicians and patients considered these concepts to be valuable. We have, however, now generated proof of concept, as hoped, and demonstrated the feasibility of measuring neurologic dysfunction in OSA patients by way of the KDT.

**Conclusions**

A novel, objective physical measure of neurologic function, the KDT, has demonstrated potential for measuring baseline abnormalities in patients with OSA of moderate or greater severity. Significant neurologic improvement can be objectively measured after patients are treated with CPAP. Future studies may discover KDT time thresholds for various AHI diagnostic levels in OSA suspect patients, possibly aiding clinicians’ risk stratification and management decisions.

**Authors’ Note**

Posters of this work were presented at the North American Primary Care Research Group Annual Meeting November 12, 2018 in Chicago IL USA, the International Forum for Quality and Safety
in Healthcare, Glasgow Scotland United Kingdom, March 28-29, 2019 and at Optometry’s Meeting, St. Louis MO USA, June 19-23, 2019.

Declaration of Conflicting Interests
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Lori Grover, OD, PhD, was Senior Vice President for Policy, King-Devick Technology, during the conceptualization and conduct of this project and reports a current financial interest in the company.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by a Mayo Clinic Arizona Research Committee Small Project Grant (#17-003889). The use of the REDCap database is supported by Mayo Clinic Center for Clinical and Translational Science, which is supported by CTSA Grant Number UL1 TR000135 from the National Center for Advancing Translational Science (NCATS). King-Devick Technology provided in kind funding for the use of the King-Devick Test in association with Mayo Clinic for this study.

ORCID iD
Michael L. Grover https://orcid.org/0000-0001-8558-7899

References
1. Epstein LJ, Kristo D, Strollo PJ Jr, et al; Adult Obstructive Sleep Apnea Task Force of the American Academy of Sleep Medicine. Clinical guideline for the evaluation, management and long-term care of obstructive sleep apnea in adults. J Clin Sleep Med. 2009;5:263-276.
2. Qaseem A, Dallas P, Owens DK, Starkey M, Holty JE, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Diagnosis of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2014;161:210-220.
3. Galetta KM, Liu M, Leong DF, Ventura RE, Galetta SL, Balcer LJ. The King-Devick test of rapid number naming for concussion detection: meta-analysis and systematic review of the literature. Concussion. 2015;1:CNC8.
4. King AT. The Proposed King-Devick Test and Its Relation to the Pierce Saccade Test and Reading Levels. Chicago, IL: Carl Shepherd Memorial Library, Illinois College of Optometry; 1976.
5. Ventura RE, Balcer LJ, Galetta SL. The Concussion Toolbox: the role of vision in the assessment of concussion. Semin Neurol. 2015;35:599-606.
6. Galetta KM, Chapman KR, Essis MD, et al. Screening utility of the King-Devick test in mild cognitive impairment and Alzheimer disease dementia. Alzheimer Dis Assoc Disord. 2017;31:152-158.
7. Davies EC, Henderson S, Balcer LJ, Galetta SL. Residency training: the King-Devick test and sleep deprivation: study in pre and post-call neurology residents. Neurology. 2012;78:e103-e106.
8. Bernstein JPK, Langfitt J. The King-Devick test as a predictor of cognitive effects after chronic partial sleep restriction: a pilot study. Sleep Biol Rhythms. 2017;15:67-73. doi:10.1007/s41105-016-0081-7
9. Lin TP, Adler CH, Hentz JG, Balcer LJ, Galetta SL, Devick S. Slowing of number naming speed by King-Devick test in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:226-229. doi:10.1016/j.parkreldis.2013.10.009
10. Stepanek J, Pradhan GN, Cocoo D, et al. Acute hypoxic hypoxia and isocapnic hypoxia effects on oculometric features. Aviat Space Environ Med. 2014;85:700-707.
11. Stepanek J, Cevette M, Pradhan GN, et al. Early detection of hypoxia-induced cognitive impairment using the King-Devick test. Aviat Space Environ Med. 2013;84:1017-1022.
12. Flemons WW, Whitelaw WA, Brant R, Remmers JE. Likelihood ratios for a sleep apnea clinical prediction rule. Am J Respir Crit Care Med. 1994;150(5 pt 1):1279-1285.
13. Grover M, Mookadam M, Chang YH, Parish J. Validating the diagnostic accuracy of the sleep apnea clinical score for use in primary care populations. Mayo Clin Proc. 2016;91:469-476. doi:10.1016/j.mayocp.2016.01.022
14. Grover M, Mookadam M, Chang YH, Parish JM. Obstructive sleep apnea: a better Dx model for primary care. J Fam Pract. 2018;67:E1-E7.
15. Gali B, Whalen FX, Schroeder DR, Gay PC, Plevak DJ. Identification of patients at risk for postoperative respiratory complications using a preoperative obstructive sleep apnea screening tool and post anesthesia care assessment. Anesthesiology. 2009;110:869-877.
16. Qaseem A, Holty JE, Owens DK, Dallas P, Starkey M, Shekelle P; Clinical Guidelines Committee of the American College of Physicians. Management of obstructive sleep apnea in adults: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2013;159:471-483.